Identity
- Security key
- 19395
- Ticker
- NUVB
- Type
- CS — Common Stock
- Exchange
- New York Stock Exchange(XNYS)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-02-10
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- NUVB
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,254,211,155.86
- Shares outstanding (class)
- 351,123,233
- Shares outstanding (weighted)
- 351,123,233
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 305
- Location
- NEW YORK, NY
- Homepage
- https://www.nuvationbio.com
- Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.